+A -A

Tabela:
Comparative View:

2Q18 Create chart
Net sales revenues 1,167,477
Change in Fair Value of Biological Assets 29,271
Cost of Goods Sold -690,982
Depreciation / Amortization / exhaustion -131,773
Exhaustion of biological assets -64,135
Gross Profit 309,858
Selling Expenses -163,779
General and Administrative Expenses -42,553
Management Compensation -4,193
Other Operating Compensation 194,472
Equity income from subsidiaries 0
Operating Profit before Financial Income and Equity 293,805
Financial Income 39,965
Financial Expenses -88,509
Income Before Income Tax and Social Contribution 245,261
Income and social contribution taxes - current -98,089
Income Tax and Social Contribution - Deferred 19,412
Effect profit from discontinued operation 0
Net Income 166,584
Recurring Net Income 27,498
Recurring EBITDA 220,019
EBITDA Margin 19.8 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza